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Abstract: Eighteen (3R) and (3R,4R)-N-phenyl-, N-phenylalkyl and N-arylsuccinimides 
were prepared with high enantioselectivity by biotransformation of maleimides with  
A. fumigatus. This environmentally friendly, clean and economical procedure was performed 
by the whole-cell fungal bioconversion methodology. Their corresponding eighteen racemic 
succinimides were prepared instead by synthetic methods. Both, the racemic and the chiral 
succinimides were tested simultaneously by the microbroth dilution method of CLSI 
against a panel of human opportunistic pathogenic fungi of clinical importance. Chiral 
succinimides showed higher antifungal activity than the corresponding racemic ones and 
the differences in activity were established by statistical methods. The bottlenecks for 
developing chiral drugs are how to obtain them through a low-cost procedure and with high 
enantiomeric excess. Results presented here accomplish both these objectives, opening an 
avenue for the development of asymmetric succinimides as new antifungal drugs for 
pharmaceutical use. 
Keywords: biotransformation; Aspergillus fumigatus; enantioselective reduction; enhanced 
antifungal activity; chiral succinimides; methylated succinimides 
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1. Introduction 
Chiral succinimides, containing asymmetric carbons (in position 3- or 3,4- of the imido ring) have 
demonstrated to be core structural units with interesting biological activities. They have shown 
anxiolytic, antidepressant effects, and the ability to inhibit protein synthesis and human enzymes, such 
as leucocyte elastase, cathepsin G, proteinase 3 and glycosidase, among others. As a consequence, they 
have become good clinical drug candidates for several diseases [1–6]. 
Regarding antimicrobial activity, the chiral succinimides andrimid and moraimide B showed potent  
in vitro antibacterial activity against antibiotic-resistant human pathogens as methicillin-resistant 
Staphylococcus aureus [7]. In turn, hirsutellones inhibited the growth of Mycobacterium tuberculosis [4]. 
These findings have led to an increased interest in the clinical use of these asymmetric structures as a 
class of potential antimicrobial agents. 
The bottleneck for developing chiral drugs for pharmaceutical use is to obtain them in a cheap and 
friendly procedure with high enantiomeric excesses (ees). Asymmetric synthesis by chemical 
procedures typically requires the use of expensive catalysts containing transition metal ions [8], which 
often prevents its commercial development. In contrast, the application of biocatalysts using whole 
cells in their native forms in aqueous/organic media has shown to be a highly selective, 
environmentally safe and cost effective method of producing enantiomeric compounds [9–12]. 
In the course of our project aimed at generating new chiral compounds through fungal 
biotransformations, we previously reported the preparation of (3R)-(+)-methyl-N-phenylsuccinimide 
(1a) and (3R,4R)-(+)-dimethyl-N-phenylsuccinimide (2a). These compounds were obtained in >99% ee 
by bioconversion of 3-methyl-N-phenyl- and 3,4-dimethyl-N-phenylmaleimide with Aspergillus fumigatus 
ATCC 26934, which proved to be the most effective catalyst among the fifteen strains tested [13]. In a 
subsequent paper, we reported the production of (3R)-(+)-methyl-N-phenylalkylsuccinimides 1b–e and 
(3R,4R)-(+)-dimethyl-N-phenylalkylsuccinimides 2b–e [alkyl chain = (CH2)n (n = 1–4)] (Figure 1) 
with excellent enantioselectivities (>99% ee) from 3-methyl- and 3,4-dimethyl-N-phenyl-
alkylmaleimides, with the same A. fumigatus strain [14]. 
Figure 1. Structures of (3R)-(+)-methyl-N-phenylsuccinimide 1a, (3R,4R)-(+)-dimethyl-N-
phenylsuccinimide 2a, (3R)-(+)-methyl-N-phenylalkylsuccinimides 1b–e and (3R,4R)-(+)-
dimethyl-N-phenylalkylsuccinimides 2b–e [alkyl chain = (CH2)n (n = 1–4)]. 
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This prompted us to expand the knowledge on the ability of A. fumigatus to stereoselectively 
hydrogenate eight related 3-methyl-N-arylmaleimides to produce asymmetric succinimides 3–10 
(Scheme 1). These compounds possess a substituted benzene ring with either electron-withdrawing or 
electron-donor groups on its p- or o-positions. It is known that the application of the same microorganism 
on different substrates does not always result in similar transformations or enantioselectivities of 
catalyzed reactions. 
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Scheme 1. Biotransformation of 3-methyl-N-arylmaleimides 11–18 to (3R)-(+)-methyl-N-
arylsuccinimide 3–10 with Aspergillus fumigatus ATCC 26934. 
 
Chiral compounds 3–10, along with the previously obtained chiral 1a–e and 2a–e, were tested here 
for antifungal properties against a panel of human opportunistic pathogenic fungi using standardized 
procedures. In addition, racemic succinimides (±)-1a–e; -2a–e; -3–10 were synthesized and tested 
simultaneously against the same panel of fungi in order to compare their antifungal activities. It is well 
known that isomers can differ in their biological activities, thus the knowledge of the properties of 
both, racemic and enantiomeric forms of a compound is of great significance in the pharmaceutical 
field, leading to a better understanding of the concentration-effect relationships, adverse effects, 
activity or toxicity [15]. 
2. Results and Discussion 
For the sake of simplicity, the thirty six compounds: racemic (rac)- and chiral 1a–e, 2a–e, 3–10, 
were grouped into three classes: (A) (rac)- and (3R)-methyl-N-phenyl- and N-phenylalkyl-succinimides 
1a–1e; (B) (rac)- and (3R,4R)-dimethyl-N-phenyl- and N-phenylalkyl- succinimides 2a–2e; and (C) 
(rac)- and (3R)-methyl-N-arylsuccinimides 3–10. 
As stated above, (3R)- and (3R,4R)-succinimides of groups (A) and (B) (compounds 1a–e and 2a–e) 
were previously obtained with >99% ee by fungal biotransformation of the respective maleimides with 
A. fumigatus ATCC 26934 [13,14,16]. In turn, racemic ones were obtained by catalytic hydrogenation 
of the respective maleimides, as previously reported [14]. 
Chiral compounds of group C [(3R)-3–10)], on the other hand, were obtained by submitting the 
respective maleimides 11–18 to biotransformation with the same strain of A. fumigatus used for 
obtaining chiral succinimides of groups (A) and (B) (Scheme 1). (Rac)-3–10 were obtained by 
catalytic hydrogenation with H2 (Pd/C). In turn, maleimides 11–18 were obtained following reported 
procedures [14]. 
The structures of 3–10 were corroborated by MS and 1H- and 13C-NMR. To assist in the assignment 
of both the absolute configuration and the ee of each chiral succinimide, R-enantiomers of 3–10 were 
also synthesized from (R)-2-methylsuccinic acid 19 and the respective anilines 20–27 (Scheme 2) [17]. 
Synthetic (3R)-3–10 were all dextrorotatory, therefore indicating that the biotransformation products  
(+)-3–10 had the R-configuration. 
Chiral GC of rac- and (3R)-(3–10) allowed us to determine that (3R)-enantiomers 3–10 eluted 
before the S-ones. These data were used to determine the ee of each biotransformation mixture and to 
confirm its absolute configuration. Results showed that 11–18 were converted into (3R)-(+)-3–10 with 
ee ≥ 98%. Table 1 shows % conversion; % ee and absolute configurations of 3–10 [data of succinimide 
R-1a, obtained from 3-methyl-N-phenylmaleimide (28) [13], were also included]. 
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Scheme 2. Synthesis of (3R)-methyl-N-aryl-succinimides 3–10 from (2R)-methylsuccinic 
acid 19 and respective anilines 20–27. 
 
Table 1. Biotransformation of 3-methyl-N-arylmaleimides 11–18 to (3R)-(+)-methyl-N-
arylsuccinimides 3–10. 
 
Substrate R1 R2 Product % ee % Conv. 
11 CH3 H (R)-(+)-3 97 93 
12 OCH3 H (R)-(+)-4 >99 97 
13 NO2 H (R)-(+)-5 98 95 
14 F H (R)-(+)-6 98 99 
15 Cl H (R)-(+)-7 97 91 
16 Br H (R)-(+)-8 98 81 
17 H CH3 (R)-(+)-9 98 65 
18 F F (R)-(+)-10 99 55 
28 * H H (R)-(+)-1a >99 99 
* Results previously reported [13]; % ee: % enantiomeric excess (calculated by chiral GC); % Conv: 
Conversion percentages (determined by GC analysis by using the TIC (total ion current) with the following 
equation: % conversion: product TIC/(product TIC + substrate TIC) × 100. 
The above results expand the knowledge on the ability of A. fumigatus ATCC 26934 to 
enantioselectively hydrogenate eight related prochiral 3-methyl-N-arylmaleimides 11–18 to produce 
chiral succinimides (3R)-3–10 with high enantioselectivity and in high yields. The fungus showed the 
same enantioface preference, irrespective of the substituent on the benzene ring which was the same 
results that has been observed with their analogues 1a–e and 2a–e [13,14]. To our knowledge, there are 
no previous reports on chiral synthesis of (3R)-methyl-N-arylsuccinimides 3, 5–10 by any of the 
chemical or enzymatic methods. Instead, (3R)-(+)-4 has been previously obtained by biotransformation 
with the plant Marchantia polymorpha [18]. 
Compounds (3R)-(3–10), along with the previously obtained chiral compounds 1a–e and 2a–e, 
were tested for antifungal properties against a panel of eleven human opportunistic pathogenic fungi 
comprising yeasts (Candida spp., Cryptococcus neoformans, Saccharomyces cerevisiae and the 
dermatophytes Microsporum gypseum, Trichophyton rubrum and Trichophyton mentagrophytes). The 
selection of these species was due to their high clinical incidence mainly among immunocompromised 
patients. Thus, species of the genus Candida are among the leading causes of nosocomial, blood 
stream infections worldwide and, although C. albicans was in the past the usual species associated with 
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invasive infections, at present non-albicans Candida spp. (C. tropicalis, C. glabrata, C. parapsilopsis, 
C. krusei and C. lusitaneae) comprise more than half of human candidiasis isolates [19]. 
In turn, C. neoformans was selected because it remains an important life-threatening species for 
immunocompromised hosts, particularly for patients infected with HIV and therefore, new compounds 
that act against this fungus are highly welcome [20,21]. Regarding dermatophytes of the genus 
Microsporum and Trichophyton, they were selected because both genera are the cause of approximately 
80–93% of chronic and recurrent human superficial infections which, although not life-threatening, 
diminish the quality of life of patients because they are difficult to eradicate [22]. 
To determine the Minimum Inhibitory Concentration (MIC), amounts of compounds from 250 μg·mL−1 
were incorporated into growth media according to the CLSI standardized procedures [23,24]. Amphotericin 
B, terbinafine, and ketoconazole were used as positive controls. The Enhancement Ratio (ER), which 
is a measure of how many-fold the MIC was reduced in each enantiomeric compound compared to its 
corresponding racemic one, was calculated as the ratio between MIC (rac)/MIC (enantiomer). Results 
are shown in Table 2. 
Table 2. Antifungal activity (MICs in μg·mL−1) of 3-methyl-N-phenyl- or N-
phenylalkylsuccinimides 1a–e (A); 3,4-dimethyl-N-phenyl- or phenylalkylsuccinimides  
2a–e (B); and 3-methyl-N-arylsuccinimides 3–10 (C), in their racemic and enantiomeric 
forms against a panel of yeasts and dermatophytes. 
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  Type n Conf. Ca 1 Ct 2 Ck 3 Cg 4 Cp 5 Cl 6 Sc 7 Cn 8 Mg 9 Tr 10 Tm 11
1 
1a A 0 - 
R- 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 31.3 62.5 
rac- 125 125 125 125 125 125 125 125 62.5 125 62.5 
ER 2 2 2 2 2 2 2 2 - 4 - 
1b A 1 - 
R- 15.6 31.3 62.5 62.5 62.5 31.3 62.5 15.6 125 62.5 62.5 
rac- 62.5 125 125 125 125 125 125 62.5 250 125 250 
ER 4 4 2 2 2 4 2 4 2 2 4 
1c A 2 - 
R- 31.3 62.5 125 62.5 31.3 62.5 62.5 62.5 125 62.5 31.3 
rac- 125 125 125 125 125 125 125 125 125 62.5 62.5 
ER 4 2 - 2 4 2 2 2 - - 2 
1d A 3 - 
R- 62.5 125 125 62.5 125 125 125 62.5 62.5 125 62.5 
rac- 125 125 125 125 125 125 125 125 125 250 250 
ER 2 - - - - - - 2 2 2 4 
1e A 4 - 
R- 31.3 31.3 62.5 125 62.5 125 62.5 31.3 125 62.5 31.3 
rac- 62.5 125 125 125 125 125 125 125 250 125 125 
ER 2 4 2 - 2 - 2 4 2 2 4 
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Table 2. Cont. 
  Type n Conf. Ca 1 Ct 2 Ck 3 Cg 4 Cp 5 Cl 6 Sc 7 Cn 8 Mg 9 Tr 10 Tm 11
2 
2a B 0 - 
3R,4R- 31.3 31.3 62.5 62.5 31.3 62.5 62.5 62.5 125 125 62.5 
rac- 125 62.5 62.5 125 62.5 62.5 125 125 125 125 125 
ER 4 2 - 2 2 - 2 2 - - 2 
2b B 1 - 
3R,4R- 31.3 62.5 62.5 125 62.5 62.5 125 62.5 62.5 62.5 31.3 
rac- 125 125 125 125 125 125 125 125 62.5 62.5 125 
ER 4 2 2 - 2 2 - 2 - - 4 
2c B 2 - 
3R,4R- 15.6 125 125 62.5 62.5 62.5 125 62.5 125 125 62.5 
rac- 125 125 250 125 250 125 125 125 250 250 62.5 
ER 8 - 2 2 4 2 - 2 2 2 - 
2d B 3 - 
3R,4R- 31.3 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 31.3 31.3 
rac- 62.5 125 125 125 125 250 125 125 125 62.5 125 
ER 2 2 2 2 2 4 2 2 2 2 4 
2e B 4 - 
3R,4R- 62.5 62.5 62.5 62.5 62.5 62.5 62.5 31.3 62.5 62.5 62.5 
rac- 125 125 62.5 125 125 125 125 125 125 125 125 
ER 2 2 - 2 2 2 2 4 2 2 2 
3 C 0 4'-CH3 
R- 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 125 125 125 
rac- 250 250 125 125 250 250 125 62.5 250 250 250 
ER 4 4 2 2 4 4 2 - 2 2 2 
4 C 0 4'-OMe 
R- 125 62.5 62.5 62.5 62.5 62.5 125 62.5 125 125 125 
rac- 250 125 125 125 125 125 125 62.5 250 250 250 
ER 2 2 2 2 2 2 - - 2 2 2 
5 C 0 4'-NO2 
R- 62.5 125 62.5 125 62.5 125 125 62.5 125 125 125 
rac- 250 125 125 125 125 125 125 125 250 250 250 
ER 4 - 2 - 2 - - 2 2 2 2 
6 C 0 4'-F 
R- 62.5 62.5 31.3 62.5 31.3 62.5 62.5 62.5 62.5 62.5 62.5 
rac- 250 250 125 125 250 250 125 62.5 125 125 125 
ER 4 4 4 2 8 4 2 - 2 2 2 
7 C 0 4'-Cl 
R- 125 62.5 125 62.5 125 62.5 62.5 31.3 125 125 125 
rac- 250 250 125 250 250 250 125 125 250 250 250 
ER 2 4 - 4 2 4 2 4 2 2 2 
8 C 0 4'-Br 
R- 125 62.5 62.5 62.5 62.5 62.5 62.5 62.5 62.5 125 125 
rac- 250 250 125 125 250 250 125 125 125 250 125 
ER 2 4 2 2 4 4 2 2 2 2 - 
9 C 0 2'-CH3 
R- 125 125 62.5 125 125 125 125 62.5 125 125 125 
rac- 250 125 125 125 250 125 125 125 250 250 250 
ER 2 - 2 - 2 - - 2 2 2 2 
10 C 0 2',4'-F2 
R- 62.5 62.5 31.3 62.5 31.3 125 62.5 62.5 62.5 62.5 125 
rac- 250 250 125 125 250 250 125 125 125 250 250 
ER 4 4 4 2 8 2 2 2 2 4 2 
AmphotericinB 0.97 0.48 0.49 0.49 0.98 0.98 0.48 0.24 0.12 0.06 0.06 
Ketoconazole 0.48 0.12 62.5 1.95 0.98 0.98 0.48 0.24 0.06 0.03 0.03 
Terbinafine - - - - - - - - 0.03 0.01 0.03 
1: Candida albicans ATCC 10231, 2: C. tropicalis CCC 131-2000: C. krusei CCC 117-2000, 4: C. glabrata 
CCC 115-2000, 5: C. parapsilosis CCC 124-2000, 6: C. lusitaniae CCC 134-2000, 7: Saccharomyces cerevisiae 
ATCC 9763, 8: Cryptococcus neoformans ATCC 32264, 9: Microsporum gypseum CCC 115-2000, 10: 
Trichophyton rubrum CCC 113 2000, 11: T. mentagrophytes ATCC 9972. CCC = Colección de Cultivos del 
CEREMIC (Centro de Referencia en Micología). ATCC: American Type Culture Collection. Conf: 
configuration; ER = MIC (rac)/MIC (R form). 
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The comparison of the 198 MICs of racemic mixtures (18 compounds x 11 fungi) with the same 
number of MICs of enantiomers, allowed us to detect that 158 MICs of chiral forms (80%) were 
statistically significantly lower (p < 0.05) than the corresponding racemic form ones. Of them, 117 
MICs were two orders of magnitude lower (ER = 2); 38 MICs were four-fold lower (ER = 4), and 
three MICs were eight-fold lower (ER = 8). C. albicans was shown to be the most sensitive species to 
chirality, showing enhancements in all pairs of compounds tested. The statistical analyses were 
performed by the non-parametric ANOVA, Kruskal-Wallis test followed by Dunn’s multiple 
comparisons and Wilcoxon’s signed rank test (p < 0.05). 
This overall trend of a better antifungal behavior of (3R)- and (3R,4R)- forms, with respect to 
racemic ones against the whole panel of fungi, was analyzed within each group of compounds for each 
type of fungus (yeasts and dermatophytes) (Figure 2). Each graph shows the percentage of MICs  
of each value, calculated as follows: [number of MICs of each value (250, 125, 62.5, 31.3 and  
15.6 µg·mL−1) × 100/total number of MICs] displayed by enantiomeric forms and by racemic mixtures 
within each group of compounds. The associations between MIC values and enantiomeric or racemic 
forms within each group and type of fungi for the different groups were established with the Score’s 
test (p < 0.05) [25]. 
Figure 2. Percentages of the different MIC values (number of MICs at each concentration/total 
number of MICs) × 100, for the enantiomeric (3R) or (3R,4R) and racemic forms of 
succinimides of either group (A), (B), or (C) acting against yeasts and dermatophytes. 
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To corroborate the above findings from another point of view, we compared the percentages of 
fungal growth inhibition for the enantiomeric form and the racemic mixture of each compound, at a 
fixed concentration. Figure 3 shows the comparative antifungal inhibitory activities of chiral vs 
racemic forms of each of the eighteen structures tested at 125 µg·mL−1 as a measure of % of growth of 
C. albicans. 
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Figure 3. Comparative values of the inhibitory activities of antifungal succinimides in their 
enantiomeric and racemic forms (at 125 μg/mL) expressed as percentage of growth against 
Candida albicans ATCC 10231. * p < 0.05. 
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It can be observed in the three groups, that each enantiomer showed a significantly lower percent of 
growth that its respective racemic form, confirming the previous analyses. These comparisons between 
groups were performed with Student’s t test. 
It is worth noting that the overall antifungal behavior of chiral forms was better than that of racemic 
ones, irrespective of the succinimides’ N-substituents, since chiral succinimides with or without an 
alkyl chain between the N atom and the phenyl group, or with or without substituents in the 2' and  
4'-positions of the benzene ring, showed better antifungal activity than their corresponding racemic forms. 
3. Experimental 
3.1. General 
Solvents and reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) and were purified 
in the usual manner. 1H- and 13C-NMR spectra were recorded on a Bruker (Karlsruhe, Germany) 300 
MHz NMR spectrometer. Compounds were dissolved in deuterated solvents from commercial sources 
(Sigma-Aldrich) with tetramethylsilane (TMS) as the internal standard. Chemical shifts (δ) are 
reported in ppm relative to the solvent peak (CHCl3 in CDCl3 at 7.26 ppm for protons and at 77.0 ppm 
for carbons). Signals are designated as follows: s, singlet; d, doublet; dd, doublets of doublets; t, 
triplet; m, multiplet; q, quartet. Melting points were obtained on or using an Electrothermal apparatus 
(Southend-on-Sea, Essex, UK) and are uncorrected. Optical rotations were measured with a Jasco 
DIB-1000 (Easton, USA) at room temperature. GC analyses were performed on a CG-MS Turbo Mass 
Perkin Elmer (Waltman, MA, USA), equipped with a fused silica gel column (SE-30 25 m × 0.22 mm 
I.D.) with He as a carrier gas in a column PE1 30 m × 0.25 mm (I.D.), film 0.1 μm, ionization energy 
70 eV with a temperature program of 70–200 °C at 10 °C min−1; total time 30 min. Chiral gas 
chromatograms were obtained with a CG-MS QP2010-Plus (Shimadzu, Kioto, Japan), with He as a 
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carrier gas on a Beta Dex-325 column (30 m × 0.25 mm I.D.), ionization energy 70 eV, with a 
temperature program of 60–200 °C at 2 °C·min−1; total time 80 min. 
3.2. Synthesis 
3-Methyl-N-arylmaleimides 11–18. The synthesis of maleimides 11–18 was performed by mixing an 
equimolecular amount of substituted anilines 20–27 (5 mmol), dissolved in CHCl3 (1 mL), and maleic 
anhydride 29 in CHCl3 (5 mL) and stirring during 1 h. The solid which precipitated out of the reaction 
mixture (maleamic acid) was filtered off. The whole amount of maleamic acid was dissolved in acetic 
anhydride (5 mL) and sodium acetate (100 mg) was added. The mixture was heated for 2 h under 
reflux. The reaction was cooled, quenched with water and the aqueous solution was extracted with 
Et2O, dried over Na2SO4, filtered, and the solvent evaporated. The product was purified by silica gel 
column chromatography using a mixture of hexane and ethyl acetate (9:1) as eluent. Spectroscopic 
NMR data of compound 12 was identical to that previously reported [18]. Compounds 11, 13–18 have 
been previously reported by Chemical Abstract Service (CAS) (11: CAS 3120-12-5, 13: CAS 10490-21-8, 
14: CAS 883033-95-2, 15: CAS 59648-09-8, 16: CAS 134939-24-5, 17: CAS 131406-19-4, 18: CAS 
124704-71-8) but, to the best of our knowledge, complete NMR spectral data were not available in the 
literature, so below, the complete spectroscopic data of these compounds are described. 
3-Methyl-N-(4'-methylphenyl)maleimide (11). White solid. Mp: 92–95 °C. Yield: 73%. 1H-NMR 
(CDCl3): 2.17 (3H, d, J = 1.8 Hz, CH3); 2.37 (3H, s, CH3); 6.46 (1H, q, J = 1.8 Hz, H-3); 7.13–7.33 
(4H, m, HAr) ppm. 13C-NMR (CDCl3): 11.2; 21.1; 125.9; 127.4; 128.9; 129.7; 137.8; 145.7; 169.8; 
170.8 ppm. MS: m/z 201 (M+, 100%), 202 (M++1, 13%). 
3-Methyl-N-(4'-methoxyphenyl)maleimide (12). White solid. Mp: 99–101 °C. Yield: 62%. 1H-NMR 
(CDCl3): δ 2.17 (3H, d, J = 1.8 Hz, CH3); 3.83 (3H, s, OCH3); 6.46 (1H, q, J = 1.8 Hz, H-3); 6.97 (2H, d, 
J = 8.9 Hz, H-3',5'); 7.23 (2H, d, J = 8.9 Hz, H-2';6') ppm. 13C-NMR (CDCl3): 11.2; 55.5; 114.4; 
124.3; 127.4; 127.5; 145.7; 159.0; 169.9; 170.9 ppm. MS: m/z 217 (M+, 100%), 218 (M++1, 13%). 
3-Methyl-N-(4'-nitrophenyl)maleimide (13). White solid. Mp: 126–128 °C. Yield: 51%. 1H-NMR 
(CDCl3): 2.11 (3H, d, J = 1.8 Hz, CH3); 6.48 (1H, q, J = 1.8 Hz, H-3); 7.62 (2H, d, J = 9.3 Hz, H-2',6'); 
8.22 (2H, d, J = 9.3 Hz, H-3',5') ppm. 13C-NMR (CDCl3): 11.2; 124.4; 125.2; 127.9; 137.5; 146.0; 
146.4; 168.5; 169.7 ppm. MS: m/z 232 (M+, 100%), 233 (M++1, 13%). 
3-Methyl-N-(4'-fluorophenyl)maleimide (14). White solid. Mp: 122–125 °C. Yield: 72%. 1H-NMR 
(CDCl3): 2.18 (3H, d, J = 1.8 Hz; CH3); 6.48 (1H, q, J = 1.8 Hz, H-3); 7.09–7.19 (2H, m, H-2';6'); 
7.28–7.36 (2H, m, H-3';5') ppm. 13C-NMR (CDCl3): 11.0; 115.8 (d, J = 22.7 Hz); 127.1 (d, J = 8.9 Hz); 
136.6; 139.8; 145.8; 161.4 (d, J = 248.5 Hz); 168.6; 169.5 ppm. MS: m/z 205 (M+, 100%),  
206 (M++1, 12%). 
3-Methyl-N-(4'-chlorophenyl)maleimide (15). White solid. Mp: 127–130 °C. Yield: 46%. 1H-NMR 
(CDCl3): 2.15 (3H, d, J = 1.3 Hz; CH3); 7.01 (1H, d, J = 1.6 Hz, H-3); 7.26 (2H, d, J = 8.8 Hz, H-3',5'); 
7.44 (2H, d, J = 8.7 Hz, H-2',6') ppm. 13C-NMR (CDCl3): 11.0; 126.2; 129.1; 136.4; 139.6; 142.3; 
150.0; 168.4; 180.7 ppm. MS: m/z 221 (M+, 100%); 223 (M++2, 32%); 222 (M++1, 12%). 
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3-Methyl-N-(4'-bromophenyl)maleimide (16). White solid. Mp: 142–144 °C. Yield: 56%. 1H-NMR 
(CDCl3): 2.17 (3H, d, J = 1.8 Hz, CH3); 6.48 (1H, q, J = 1.8Hz, H-3); 7.23–7.29 (2H, d, J = 8.8 Hz, 
3',5'-H); 7.53–7.61 (2H, d, J = 8.8 Hz, 2'-6'-H) ppm. 13C-NMR (CDCl3): 11.2; 121.2; 127.2; 127.6; 
130.4; 132.2; 145.9; 169.1; 170.6 ppm. MS: m/z 265 (M+, 100%), 267 (M++2, 97%), 265 (M++1, 
12%), 268 (M++3, 11%). 
3-Methyl-N-(2'-methylphenyl)maleimide (17). White solid. Mp: 55–57 °C. Yield: 52%. 1H-NMR 
(CDCl3): 2.15 (3H, d, J = 1.8Hz, CH3); 2.16 (3H, s, CH3); 6.47 (1H, q, J = 1.8 Hz, H-3); 7.10 (1H, d,  
J = 7.3, H-3'); 7.23–7.35 (3H, m, H-4'-6') ppm. 13C-NMR (CDCl3): 11.1; 17.9; 126.8; 127.7; 128.7; 
129.5; 130.6; 131.1; 136.6; 146.2; 169.7; 170.7 ppm. MS: m/z 203 (M+, 100%), 208 (M++1, 13%).  
3-Methyl-N-(2',4'-difluorophenyl)maleimide (18). White solid. Mp: 80–82 °C. Yield: 85%. 1H-NMR 
(CDCl3): 2.01 (3H, d, J = 1.8Hz, CH3); 6.40 (1H, d, J = 1.8Hz, H-3); 6.89 (2H, q, J = 9.3 Hz; 5',6'-H); 
7.15 (1H, dt, J = 8.6Hz; 3'-H) ppm. 13C-NMR (CDCl3): 10.8; 104.93 (dd, J = 26.38, 23.90 Hz); 111.78 
(dd, J = 22.62, 3.66 Hz); 115.66 (dd, J = 13.43, 3.89 Hz); 127.8; 130.8 (dd, J = 10.09, 1.35 Hz); 146.4; 
158.1 (dd, J = 254.42, 12.75 Hz); 162.5 (dd, J = 250.8, 11.3 Hz); 168.5; 169.7 ppm. MS: m/z 223  
(M+, 100%), 224 (M++1, 12%).  
Rac-3-methyl-N-arylsuccinimides 3–10. Each maleimide 11–18 (2 mmol) was dissolved in CH2Cl2  
(2 mL) to which a catalytic amount of 5% Pd/C was added. Then, the mixture was exposed to a H2 
atmosphere at room temperature for 2 h. The crude mixture was filtered and the solvent was 
evaporated. The resulting product was purified by silica gel column chromatography using a mixture 
of hexane and ethyl acetate (9:1) as eluent.  
(3R)-(+)-Methyl-N-arylsuccinimides 3–10. A mixture of (R)-(+)-methylsuccinic acid 19 (5.0 mmol in 
water) and substituted anilines 20–27 were maintained at 170 °C for 2 h and then cooled to 20 °C. The 
aqueous solution was extracted with Et2O, dried over Na2SO4, filtered, and the solvent evaporated. The 
mixtures were subjected to silica gel column chromatography using a mixture of hexane and ethyl 
acetate (9:1) as eluent. Compounds 6, 9 and 10 (rac or R) are not described in the literature. 
Spectroscopic NMR data of compound 4 was identical to that previously reported [18]. Compounds 
rac-3, rac-5, rac-7, rac-8 have been previously reported by Chemical Abstract Service (CAS) (3: CAS 
105909-89-5, 5: CAS 33624-30-5, 7: CAS 25998-50-9, 8: CAS 134939-24-5) but, to the best of our 
knowledge, complete NMR spectral data were not available in the literature, so the complete 
spectroscopic data of these compounds are described below.  
(3R)-(+)-Methyl-N-(4'-methylphenyl)succinimide (3), White solid. Mp: 113–115 °C. Yield: 58%. 1H-NMR 
(CDCl3): 1.45 (3H, d, J = 7.2 Hz, CH3); 2.38 (3H, s, CH3); 2.49 (1H, dd, J = 17.1; 3.8 Hz, H-3b); 
2.94–3.16 (2H, m, H-2;3a); 7.15 (2H, d, J = 8.4Hz, H-2';6'); 7.27 (2H, d, J = 8.5 Hz, H-3';5') ppm.  
13C-NMR (CDCl3): 16.9; 21.2; 126.2; 129.3; 129.8; 138.7; 175.6; 179.7 ppm. MS: m/z 203 (M+, 
100%), 204 (M++1, 13%). [α]27 D +5.2 ± 1.2 (c 0.76, CHCl3). 
(3R)-(+)-Methyl -N-(4'-methoxyphenyl)succinimide (4). White solid. Mp: 110–112 °C. Yield: 65%. 
1H-NMR (CDCl3): 1.44 (3H, d, J = 7.2 Hz, CH3); 2.48 (1H, dd, J = 17.1; 3.8 Hz, H-3b); 2.94–3.15 
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(2H, m, H-2 and H-3a); 3.82 (3H, s, OCH3); 6.98 (2H, d, J = 8.4 Hz, H-2';6'); 7.19 (2H, d, J = 8.5 Hz, 
H-3';5') ppm. 13C-NMR (CDCl3): 16.9; 34.8; 36.6; 55.5; 114.5; 124.6; 127.6; 159.5;175.7; 179.8 ppm. 
MS: m/z 219 (M+, 100%), 220 (M++1, 13%). [α]27 D  +4.2 ± 1.1 (c 0.96, CHCl3) 
(3R)-(+)-Methyl-N-(4'-nitrophenyl)succinimide (5. White solid. Mp: 111–112 °C. Yield: 72%. 1H-NMR 
(CDCl3): 1.46 (3H, d, J = 7.2 Hz, CH3); 2.56 (1H, dd, J = 17.1; 3.9 Hz, H-3b); 2.98–3.18 (2H, m, H-2; 
3a); 7.61 (2H, d, J = 9.3 Hz, H-2',6'); 8.34 (2H, d, J = 9.4 Hz, H-3',5') ppm. 13C-NMR (CDCl3): 16.9; 
34.9; 36.6; 123.1; 124.4; 126.8; 137.5; 174.5; 178.6; ppm. MS: m/z 234 (M+, 100%), 235 (M++1, 
12%). [α]27 D  +6.1 ± 0.9 (c 0.86, CHCl3) 
(3R)-(+)-Methyl-N-(4'-fluorophenyl)succinimide (6). White solid. Mp: 105–107 °C. Yield: 76%. 1H-NMR 
(CDCl3): 1.45 (3H, d, J = 7.2 Hz, CH3); 2.50 (1H, dd, 17.1; 3.8 Hz, H-3b); 2.98–3.19 (2H, m, H-2 and 
H-3a); 7.15 (2H, t, J = 8.7 Hz, H-2',6'); 7.28 (2H, dd, J = 8.0, 5.8 Hz, H-3',5') ppm. 13C-NMR (CDCl3): 
16.9; 34.8; 36.6; 116.2 (d, JC-F = 22.9 Hz); 128.2 (d, JC-F = 8.8 Hz); 148.5; 162.3 (d, JC-F = 248.7 Hz); 
175.3; 179.4 ppm. MS: m/z 207 (M+, 100%), 250 (M++1, 12%). [α]27 D  +4.9 ± 0.8 (c 0.72, CHCl3). 
(3R)-(+)-Methyl-N-(4'-chlorophenyl)succinimide (7). White solid. Mp: 112–113 °C. Yield: 68%. 1H-NMR 
(CDCl3): 1.46 (3H, d, J = 7.2 Hz, CH3); 2.51 (1H, dd, J = 17.1; 3.8 Hz, H-3b); 2.96–3.16 (2H, m, H-2 
and H-3a); 7.26 (2H, d, J = 8.8 Hz, H-3',5'); 7.44 (2H, d, J = 8.7 Hz, H-2',6') ppm. 13C-NMR (CDCl3): 
16.9; 34.8; 36.6; 126.2; 129.1; 136.4; 142.3; 178.4; 178.7 ppm. MS: m/z 223 (M+, 100%), 225 (M++2, 
32%), 224 (M++1, 12%). [α]27 D  +4.5 ± 1.1 (c 0.66, CHCl3). [α]27 D  +4.5 ± 1.1 (c 0.66, CHCl3). 
(3R)-(+)-Methyl-N-(4'-bromophenyl)succinimide (8). White solid. Mp: 134–136 °C. Yield: 49%. 1H-NMR 
(CDCl3): 1.46 (3H, d, J = 7.2 Hz, CH3); 2.51 (1H, dd, 17.1; 3.8 Hz, H-3b); 2.96–3.16 (2H, m, H-2 and 
H-3a); 7.19 (2H, d, J = 8.8 Hz, H-3',5'); 7.56 (2H, d, J = 8.7 Hz, H-2',6') ppm. 13C-NMR (CDCl3): 
16.8; 34.9; 36.6; 122.4; 127.9;130.9;132.3; 174.8; 179.2 ppm. MS: m/z 267 (M+, 100%), 269 (M++2, 
98%), 268 (M++1, 12%). [α]27 D  +5.6 ± 1.3 (c 0.58, CHCl3). 
(3R)-(+)-Methyl-(2'-methylphenyl)succinimide (9). White solid. Mp: 102–105 °C. Yield: 74%. 1H-NMR 
(CDCl3): 1.46 (3H, dd, J = 7.15, 1.46 Hz, CH3); 2.13 (3H, d, J = 1.87 Hz, CH3); 2.52 (1H, ddd,  
J = 16.7, 3.4, 1.6 Hz, H-3b); 2.96–3.17 (2H, m, H- 2;3a); 7.05 (1H, dd, J = 7.2, 1.1 Hz; H-4');  
7.24–7.38 (3H, m, H-3';5';6') ppm. 13C-NMR (CDCl3): 16.9; 17.5; 35.2; 36.8; 126.9; 127.9; 129.5; 
131.0; 131.2; 135.5; 175.4; i179.6 ppm. MS: m/z 201 (M+, 100%), 202 (M++1, 13%). [α]27 D  +7.3 ± 1.7 
(c 0.47, CHCl3) 
(3R)-(+)-Methyl-N-(2',4'-difluorophenyl)succinimide (10). White solid. Mp: 102–104 °C. Yield: 49%. 
1H-NMR (CDCl3): 1.45 (3H, dd, J = 7.15, 1.46 Hz, CH3); 2.52 (1H, dd, J = 3.4, 1.6 Hz, H-3b);  
2.95–3.16 (2H, m, H-2;3a); 6.79 (2H, q, J = 9.3 Hz; 5',6'-H); 7.15 (1H, dt, J = 8.6 Hz; 3'-H) ppm. 13C-NMR 
(CDCl3): 16.8; 35.2; 36.7; 105.3 (dd, J = 26.4, 23.5 Hz), 112.0 (dd, J = 22.6, 3.6 Hz), 116.08 (dd,  
J = 13.4, 3.9 Hz), 130.24 (dd, J = 10.2, 1.7 Hz), 157.7 (dd, J = 255.1, 12.8 Hz), 163.1 (dd, J = 251.9, 
11.4 Hz), 168.7; 169.2 ppm. MS: m/z 225 (M+, 100%), 226 (M++1, 12%). [α]27 D  +5.3 ± 1.4 (c 0.81, CHCl3). 
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3.3. Biotransformations 
A. fumigatus ATCC 26934 was grown on a plate with agarized Czapek culture medium for 3 days 
at 30 °C until well sporulated. 2-L Erlenmeyer flasks containing Czapek broth medium (1 L) were 
inoculated with suspensions of conidia (2–5 × 106 CFU mL−1) and incubated at 30 °C for 72 h at  
150 rpm on an orbital shaker (Innova 4000, New Brunswick Scientific Inc., Edison, NJ, USA). 
Substrates (125 mg) in DMSO (5 mL) were poured into flasks containing the fungal biomass and 
the reaction mixtures were incubated at 30 °C for 72 h on an orbital shaker (150 rpm). Culture controls 
consisted of microorganism blank in which A. fumigatus ATCC 26934 was grown without substrate 
but fed with the same amount of DMSO. Substrate controls contained the sterile medium with the 
same amount of substrate and were incubated under the above conditions. 
After incubation the mixtures were filtered, the aqueous phases were combined and extracted with 
ethyl acetate (3 × 250 mL) and the organic phases were dried over Na2SO4. Conversion percentages 
were determined by GC analysis of the crude extracts and determined by using the TIC (total ion 
current) with the following equation: % conversion: product TIC/(product TIC + substrate TIC) × 100. 
Compounds were purified by silica gel column chromatography using a mixture of hexane and ethyl 
acetate (9:1) as eluent. 
3.4. Antifungal Susceptibility Testing 
The test fungi belonged either to the American Type Culture Collection (ATCC, Rockville, MD, 
USA), or the Culture Collection of CEREMIC (Centro de Referencia en Micología-CCC, Facultad de 
Ciencias Bioquímicas y Farmacéuticas, Rosario, Argentina). Species of Candida genus: C. albicans 
ATCC 10231, C. tropicalis CCC 131-2000, C. krusei CCC 117-2000, C. glabrata CCC 115-2000,  
C. parapsilosis CCC 124-2000, C. lusitaniae CCC 134-2000; S. cerevisiae ATCC 9763; C. neoformans 
ATCC 32264, M. gypseum CCC 115-2000, T. rubrum CCC 113-2000 and T. mentagrophytes ATCC 
9972 were used. 
Strains were grown on Sabouraud-chloramphenicol agar slants at 30 °C, maintained on slopes of 
Sabouraud-dextrose agar (SDA, Oxoid), and sub-cultured every 15 days to prevent pleomorphic 
transformations. Inocula were obtained according to reported procedures [23,24] and adjusted to 1–5 × 103 
colony forming units (CFU) mL−1. 
The antifungal activity was determined by using broth microdilution techniques following the 
guidelines of the CLSI for yeasts and for filamentous fungi [23,24]. Compounds stock solutions were 
two-fold diluted from 250 to 0.24 μg ml−1 (final volume = 100 μL) and a final DMSO (Sigma) 
concentration <1% in the culture media RPMI-1640 (Sigma) buffered to pH 7.0 with MOPS (Sigma). 
The test was performed in 96 wells-microplates and included: Test wells (TW), containing the 
compound solution and the inoculum of the fungus; Growth Control Well (GCW), that contains 
compound-free medium and inoculum; Blank Test Wells (BTW), with the compound, culture medium 
and sterile water instead of inoculum; Sterility Control Well (SCW) containing the compound diluted 
in culture medium and sterile water. Ketoconazole (Sigma), terbinafine (Sigma) and amphotericin B 
(Sigma), were used as standard controls. 
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Plates were incubated in a moist, dark chamber 24 h for yeasts and 5 d for dermatophytes and  
the MIC (Minimum Inhibitory Concentration) was determined. For yeasts, microplates turbidity  
due to fungal growth were determined at 405 nm in a VERSA Max microplate reader (Molecular 
Devices, Sunnyvale, CA, USA) and the % of growth were calculated as follows: % of growth = 
[(ODTW − ODBTW)/(ODGCW − ODSCW) ×100. 
3.5. Statistical Tests 
Multiple comparisons were performed by the non-parametric ANOVA, Kruskal-Wallis test 
followed by Dunn's multiple comparisons and Wilcoxon’s signed rank test. The associations between 
MIC for the different groups were corroborated with the Score’s test [25]. Individual comparisons 
between groups were performed with Student’s t test. A value of p < 0.05 was considered significant. 
4. Conclusions 
The antifungal behavior of eighteen enantiomerically pure (3R)-methyl- and (3R,4R)-dimethyl-N-
phenyl-, N-phenylalkyl- or N-arylsuccinimides, obtained by a low-cost and environmentally friendly  
A. fumigatus-catalyzed reduction of maleimides, were compared to that of the corresponding racemic 
ones. Results showed that the biotransformation products displayed statistically significant higher 
antifungal activity against a panel of human opportunistic pathogenic fungi including yeasts as well as 
dermatophytes than racemic ones as demonstrated by different approaches. These findings can be 
highly useful for the development of chiral methylated succinimides as antifungal drugs by the 
pharmaceutical industry and in a broader sense, they open new avenues for the development of highly 
active drugs containing other 3- and 3,4-substituted chiral succinimides [26]. 
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